Vertex Pharmaceuticals

Open: 357.15 Close: 357.45 Change: 0.3

An AI to read internet: The best strategy to evaluate Vertex Pharmaceuticals Stock.

How much time have you spent trying to decide whether investing in Vertex Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals is 95.08% away from the 52-week high. The 73 analysts offering price forecasts for the company have a median target of 328.47. Vertex and Lonza announced a strategic collaboration to support the manufacture of Vertexs.

Today's News

Vertex Pharmaceuticals CRISPR Therapeutics gene editing CRisPR-Cas9 Cell & Gene Therapy advisory committee Food and Drug Administration (FDA) Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close. Vertex is a global biotechnology company that discovers and develops small-molecule drugs. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on August 1, 2023 after the financial markets close. Vertex and Lonza announced a strategic collaboration to support the manufacture of Vertexs. According to the current price, Vertex Pharmaceuticals is 95.08% away from the 52-week high. The high in the last 52 weeks was 375.93. The 73 analysts offering price forecasts for the company have a median target of 328.47. Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis. Wall Street analysts revised their ratings and price targets on several U.S.-listed companies, including Alnylam Pharmaceuticals, Labcorp and Vertex Pharmaceuticals. FDA reviewers reportedly raised questions about possible side-effects of a novel gene therapy for sickle cell disease developed by Vertex. Vertex Pharmaceuticals stock price is 355.38 USD today. The Vertex pharmaceuticals stock is currently sporting a Zacks Rank of #3 (Hold) Looking at its valuation at its forward Packs Forward P/E ratio of 24.81.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

This document will help you to evaluate Vertex Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, financial, company, price, develop, gene, and the most common words in the summary are: vertex, pharmaceutical, price, job, inc, stock, target, . One of the sentences in the summary was: Vertex Pharmaceuticals is 95.08% away from the 52-week high. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #price #job #inc #stock #target.